Johne’s disease costs the Canadian dairy industry an estimated $90 million a year through loss of production. PBD Biotech has gained funding from the Canadian government to progress development of its unique Actiphage test for mycobacterial diseases to address this major economic issue.
Vet Robert Price-Jones comments in a BBC interview that the blood test Actiphage offers the potential for eradicating bovine TB from the farm: “Early identification of animals at risk of bovine TB enables effective disease management and control.”
Salary: According to experience
CD: Not Specified
PBD Biotech is the developer of Actiphage™, a new test for bovine tuberculosis (bTB) and other mycobacterial diseases. It has a new role for molecular scientist to help this exciting new technology company, transform diagnosis of bacterial disease.
PBD Biotech’s Actiphage technology wins Royal Dairy Innovation Award 2019
Powerful diagnostics, using the latest science, are offering a new approach to disease management, explains PBD Biotech CEO Berwyn Clarke
A year since he first pitched in the REAP Start-Up Showcase (right), Dr Berwyn Clarke, Co-founder of PBD Biotech, was back to announce the first
A ground-breaking test for tuberculosis that can deliver results within six hours is on the cusp of commercialisation, says Dr Berwyn Clarke from PBD Biotech.